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Summary 
 
The isolated perfused heart is a convenient and reproducible model to test cellular and metabolic 
mechanisms of myocardial injury, and for screening drugs or interventions for cardioprotective 
properties.  
In our study, we isolated heart tissues of wistar rats fed with normal or three months with high-
fat diet (HF) and pre-treated daily for 14 days with saline or different doses of sitagliptin (25, 50, 
100 or 150 mg/kg) and assigned them into a Langendorff system through aorta cannulation, 
using prolonged and brief reperfusion protocols, for infarct size (IS) and biochemical 
measurements respectively. 
The 50 mg dose of sitagliptin exhibited a significant decrease in infarct size in both normal and 
high-fat diet animals. Gliptins are well known for their anti-hyperglycaemic and incretin 
homeostatic properties, namely the glucagon-like peptide-1 (GLP-1). Sitagliptin treatment 
showed a significant decrease in DPP-4 activity and increase in GLP-1level in normal animals 
but not in hyperlipidemic ones.  
 
We extended our measurements to cNOS activity, and endothelial nitric oxide synthase (e-NOS) 
protein expression, followed by transient receptor potential vaniloid-1 (TRPV-1) level and 
transient receptor potential canonical- 1 (TRPC-1) protein expression. A significant upregulation 
in NOS activity was the case in animal’s groups of both diet conditions. e-NOS expression, 
TRPV-1 level and TRPC-1 expression increased significantly in normal diet animals, however, 
in high-fat (HF) diet animals this upregulatory effect was abolished. 
 
Transient receptor potential vanilloid type-1 (TRPV-1) is an upstream regulator of calcitonin 
gene-related peptide (CGRP), and TRPV-1 stimulation promotes the release of CGRP, mediating 
cardioprotection. Obtained results from CGRP measurement displayed a significant increase in 
normal animals as well as in animals kept on high-fat diet, after treatment with sitagliptin.  
 
We invesitgated the effect of nitric oxide synthase (NOS) inhibition on infarct size in animal 
groups from both diets, and TRPV-1 inhibitory effect in normal animals only. The 
cardioprotective effect of sitagliptin mediated by NOS was lost in both diet conditions. Similarly, 
the inhibitory effect of TRPV-1 showed an increase in infarct size, and blockage of sitagliptin-
TRPV-1 mediated cardioprotective action. 
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Introduction 
 
The incidence of cardiovascular disorders continues to grow across worldwide, contributing to 
the largest rate of mortality and morbidity each year, including ischemic heart disease . Ischemia-
reperfusion (I/R) injury occurs when circulation is abruptly restored following prolonged 
ischemia and characterized by high levels of calcium and tissue neutrophil accumulationn 
causing cellular damage, and production of reactive oxygen species (ROS) during reperfusion, 
triggering I/R injury  
Reperfusion is  necessary for the restoration of epicardial and microvascular blood flow and the 
normal physiology of the heart, avoiding further damage to the mayocardium , however, 
exposing heart tissues to abrupt reperfusion, can lead to further myocardial damage, and 
subsequently cell death .  
Hyperlipidemia is considered a significant reason and major contributor in the development of 
ischemic heart disease and myocardial infarction (MI), responsible for lipids deposition in 
athermanous lesions and primary endothelail injury, and long-term high-fat diet (HFD) 
consumption can increase myocardial infarct size following an ischemia-reperfusion insult. 
Previously experimented pharmacological drugs under normolipidemic and hyperlipidemic 
conditions failed to make their way into clinical treatments. Therefore, finding new protective 
agents and molecular targets during I/R that can be exploited therapeutically in the aim of 
decreasing the incidence of cardiovascular events and limiting the extent of infarction is urgently 
needed.  
Dipeptidyl Peptidase-4 (DPP-4) is a widely expressed glycoprotein peptidase that exhibits 
catalytic degradation of incretins such as glucagon-like-peptide-1 (GLP-1) . A number of 
pharmaceutical products including dipeptidyl peptidase-4 (DPP-4) inhibitors such as sitagliptin 
are oral anti-diabetic drugs that inhibit the DPP-4 enzyme, avoid the degradation of incretins , 
and result in its prolonged action . Activation of GLP-1 by DPP4-4 inhibitors, limits myocardial 
infarct size (IS) and protects cardiomyocytes from cell death. 
Nitric oxide synthase (NOS) is an enzyme that catalyzes the production of nitric oxide (NO) 
from L-arginine, and exhibits cardioprotective effects by decreasing infarct size in acute 
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myocardial infarction . Endothelial NOS (e-NOS) is highly abundant in endothelail cells, as well 
as in cardiomyocytes. Up-regulation of GLP-1 can restore vascular NO bioavailability by the up-
regulation of e-NOS, and blocking DPP-4 activity plays a role in the modulation of NOS 
enzymes  
Transient receptor potential (TRP) channels, namely the canonical (TRPC) and vanilloid (TRPV) 
isoforms are the most commonly localized and essential Ca
2+
-permeable channels in vascular 
endothelial cells, ventricles, coronary blood vessels and sensory nerves innervating the heart. 
TRPV-1 are localized in the sensory nerves that surrounds the cardiovascular structure and in 
cardiomyocytes. The latter functions upon a chemical or physical stimuli like capsaicin (CAP), 
proton and heat, releasing sensory neuropeptides functioning as vasodilators, like calcitonin 
gene-related peptide (CGRP), mediating cardioprotection and regulating the cardiac function . 
Activation of endothelial nitric oxide synthase (e-NOS) mediates the endothelium-dependent 
vasodilatory actions induced by CGRP, and since e-NOS is Ca
2+
/calmodulin-dependent, its 
activity may be modulated by cytosolic Ca
2+
 levels . Although TRPC and TRPV channels play a 
fundamental role in mediating ischemia-reperfusion injury and regulating cardioprotective 
signaling; however, the activation mechanisms underlying both types of channels are still 
unknown, and further investigations are needed to testify the significance and contribution of 
CGRP in cardioprotection. 
 
Aims 
 
Due to the pleiotropic cardioprotective effect of gliptins as anti-diabetic drugs, we aimed to study 
the effect sitagliptin treatment on myocardial I/R injury in normal and high-fat diet animals, 
using an ex-vivo model. 
     We hypothesized that: 
1. Sitagliptin treatment can decrease the infarct size in both diet conditions 
2. Protective effect of sitagliptin in normal and high-fat diet animals can be mediated by: 
i. Nitric oxide synthase (NOS) 
ii. Transient receptor potential channels (TRPC, TRPV) 
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iii. Calcitonin gene-related peptide (CGRP)  
3. NOS and TRPV inhibition can block the cardioprotective effect of sitagliptin 
 
Materials and Methods 
 
In this study, we used an isolated ex-vivo perfused heart model to study ischemia-reperfusion 
(I/R) injury. This model is ideal for screening drugs or interventions for protective properties, 
because heart tissue is studied independently of circulating factors or neuroendocrine inputs from 
other organs but retains the function, composition, and architecture of the intact heart.  
 
Animals and experimental design 
 
Wistar rats were assigned into 2 different diet conditions: fed either with standard rat chow only 
or mixed with fats (High fat= HF) for 12 weeks to induce hyperlipidemia.  
Animals were then divided into 4 different experiments: 
Experiment 1. To determine the effective dose of Sitagliptin (Sitg), animals from both diets 
were randomly divided into 5 groups: (Control (Saline), Sitg (25 mg), Sitg (50 mg), Sitg (100 
mg) and Sitg (150 mg), n=8-16). Daily oral administration of different drug doses or its vehicle 
(Saline) lasted for two weeks. Animals were then anesthetized, heart tissues were excised, 
immediately placed in ice-cold saline, mounted and ligated through the aorta into the cannula of 
a Langendorff Apparatus System, and perfused with 37 °C Krebs buffer. Hearts were exposed to 
10 min perfusion, 45 min prolonged regional ischemia by LAD coronary artery occlusion, and 
120 min reperfusion. LAD was then re-ligated, and stained with Evans blue via the aortic root, to 
determine the AAR. Tissues were stored at -20 
o
C for TTC staining.  
Experiment 2. For the purpose of in vitro laboratory measurements, another set of experiments 
was carried out on 2 animal groups (Control (Saline) and Sitg (50 mg/kg/day), n=10), from both 
diets. Oral treatment lasted for 2 weeks. Same whole-heart preparation procedure as in 
experiment 1 was carried out. Hearts were exposed to 10 min perfusion, 45 min prolonged 
regional ischemia, and 10 min brief reperfusion. Tissues were clamped and stored at -80 
o
C for 
biochemical analyses. 
Experiment 3. To check the involvement of NOS in Sitg- mediated cardioprotection, four 
different animal groups (Control (Saline), Sitg (50 mg), Control (Saline) + L-NAME, and Sitg 
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(50 mg) + L-NAME, n=10-12) were studied in animals from both diets. Oral treatment lasted for 
2 weeks, with intraperitoneal (i.p) injection of NOS inhibitor (L-NAME). Same heart preparation 
procedure and I/R injury protocol were applied as in Experiment 1. Tissues were stored at -20 
o 
C 
for TTC staining and IS measurement. 
Experiment 4. To evaluate the inhibitory effect of TRPV-1, four groups only from 
normolipidemic animals (Control (Saline) + DMSO, Sitg (50 mg) + DMSO, Control (Saline) + 
CAP, and Sitg (50 mg) + CAP, n= 5-8) received 2 weeks’ oral treatments, and intraperitoneal 
injections with DMSO or TRPV-1 inhibitor (Capsazepine (CAP)). Same heart preparation 
procedure, I/R injury protocol, and tissue- staining procedure were performed similarly as in 
Experiment 1. 
Tissue staining and infarct size measurement 
 
Frozen tissues were transversely sectioned into 5-6 slices, and incubated in TTC, fixed in 
formalin, and then placed in phosphate buffer. Sections were mounted on glass slides, images 
were captured with a digital camera, and analysed with an ImageJ software.  
Serum cholesterol and triglyceride measurements 
 
Blood samples only from normal and high-fat diet animals were centrifuged, serum collected, 
cholesterol (Chol) and triglyceride (TG) levels were measured using specific reagent kits. Chol 
and TG serum concentrations were quantitatively determined based on enzymatic colorimetric 
method (phenol + aminophenazone -PAP) at 490-550 nm. Results of both measurements were 
expressed in mmol/l. 
Liver cholesterol and triglyceride measurements 
 
Liver tissues from high-fat diet animals were homogenized in ice-cold phosphate buffer saline by 
Ultra-Turrax T25 (13,500/s). Supernatants were collected, and same chol and TG kits 
(Diagnosticum Zrt) were used. Obtained results were expressed in (mmol/l). 
DPP-4 activity 
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DPP-4 activity was measured from heart tissues of normal and high-fat diet animals, using 
specific DPP-4 activity assay kit (Sigma-Aldrich). Tissues were homogenized in ice-cold assay 
Buffer, centrifuged at 13,000 x g, for 10 min at 4°C, Standard and sample fluorescence 
intensities from collected supernatants were at 360-460 nm in 96-well black plates specific for 
fluorescence assays, using fluorescence multi-well plate reader (Fluorometer).  Results are 
expressed as microunit/ml. 
Nitric oxide synthase (NOS) activity 
 
NOS activity was measured in heart tissues from animals fed with both diets, by quantifying the 
conversion of [
14
C]-labeled L-arginine to citrulline. Heart tissues were homogenized in ice-cold 
special homogenization buffer of pH 7.4. Samples were centrifuged for 30 min, at 20000 x g, and 
4°C. Samples were then incubated for 10 min at 37°C with an assay buffer. The reaction was 
terminated by addition of ice-cold DOWEX prepared in distilled water. The mixture was re-
suspended by adding ice-cold distilled water, supernatants were removed and radioactivity was 
determined by scintillation counting. The Ca
2+
 dependence of the NOS activity was determined 
by addition of ethylene glycol-bis tetraacetic acid (EGTA). NOS activity was confirmed by 
inhibition with Nω-nitro-L-arginine methyl ester (L-NNA). The i-NOS level was defined as the 
extent of citrulline formation that was inhibited by L-NNA, but not by EGTA. The cNOS 
activity was calculated from the difference between the extent of citrulline formation inhibited 
by EGTA and the total activity. This activity is referred to as cNOS, and expressed as 
pmol/min/mg protein. 
ELISA measurements (GLP-1, TRPV-1 and CGRP) 
A double-antibody sandwich ELISA kits specific for rat GLP-1, TRPV-1 and CGRP (SunRed 
Biotechnology) were used for measurements form heart tissues in both animal diets, using same 
homogenization buffer (PBS), homogenization and centrifugation procedures. Parameters were 
measured at 450 nm, and results were expressed in ng/ml for GLP-1 and TRPV-1, and ng/L for 
CGRP.  
Calcium (Ca
2+
) content  
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A Colorimetric Calcium Detection Assay Kit (Abcam) was used to determine the calcium (Ca
2+
) 
concentration in heart tissues of animals from both diets. Samples were homogenized on ice-cold 
PBS buffer, and centrifuged at a maximum speed for 2-5 min. Supernatants were collected, and 
optical densities (OD) were detected at 575 nm. Results were expressed in ng/mg protein. 
 
TRPC-1 and e-NOS and DPP-4 (CD26) protein expression by western blotting normalized 
to β-actin 
 
Measured heart tissues from both diet groups were homogenized at 13,500/s in ice-cold radio 
RIPA buffer, and Homo-buffer, for TRPC-1 and e-NOS proteins respectively. Homogenates 
were centrifuged (10-15 min, 12000 rpm, 4°C). Proteins were resolved on 8 % and 10 % sodium 
dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE), and transferred to 
nitrocellulose membranes. Blots were probed overnight (4 
o
C, and 1 % milk), with anti-TRPC-1 
rabbit primary antibody (1:500), anti- e-NOS mouse primary antibody (1:250), anti-CD26 rabbit 
primary antibody (1:500, (ab129060), and anti-beta actin mouse primary antibody (1 % BSA, 
1:4000, (ab 8226). Membranes were then incubated for 1 h at room temperature with secondary 
anti-rabbit (1:1000, (sc-2370)), secondary anti-mouse (1:5000, (sc-A9044)), secondary anti-
rabbit (1:5000, (sc-2370)), and secondary anti-mouse (1:2000, (sc-A9044)) antibodies 
conjugated with horseradish peroxidase (HRP) enzyme, for TRPC-1, e-NOS, CD26 (DPP4), and 
β-actin, respectively. Signals were developed by using enhanced chemiluminescent substrate for 
detection of HRP and exposed to Hyperfilm. Protein bands densities were analysed using the 
Image Quant Software. 
Protein determination 
 
Aliquots from diluted samples (15- or 25-fold with distilled water) were mixed with distilled 
water, and Bradford reagent. After mixing and 10 min incubation, samples were assayed 
spectrophotometrically at 595 nm (Benchmark Microplate Reader; Bio-Rad, Budapest, 
Hungary). Protein levels were expressed as mg protein/ml.  
Statistical analysis  
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All data were shown as mean ± SEM. Statistical comparisons were performed with Student’s 
two-tailed unpaired t test, one-way ANOVA multiple comparison test (Bonferroni), and two-way 
ANOVA when necessary. Differences were considered significant when P- values were less than 
0.05 (P< 0.05). 
 
 
Results 
 
Evaluation of sitagliptin effect on infarct size   
In sitagliptin (50 mg/kg/day) treated animal groups, the infarct size decreased significantly 
compared to the controls (saline), in both normal and high-fat diet animals. Although a decrease 
in infarct size was also observed in other doses, but results were not significant.  
Serum cholesterol and triglyceride 
 
Cholesterol and triglyceride measurements from serum samples revealed a significant increase in 
high-fat control animals compared to normal control group, however, no significant change was 
observed in groups treated with sitagliptin.   
Liver cholesterol and triglycerides concentration in high-fat diet animals  
 
Measurements from liver homogenates showed a significant decrease in cholesterol level in 
sitagliptin (50 mg)- treated group compared to control (saline), while no significant difference 
was observed in comparison with absolute controls. Liver triglyceride significantly increased in 
high-fat control group compared to absolute controls, but no significant change was observed in 
the group treated with sitagliptin. 
Heart tissue DPP-4 activity and GLP-1 level 
Both, DPP-4 activity and GLP-1 level were significantly upregulated after sitagliptin (50 mg) 
treatment in normolipidemic animals, while not in case of hyperlipidemia.  
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DPP-4 level in Heart tissues and Aorta’s of high-fat diet animals 
 
Results from heart tissues and aorta’s exhibited a significant reduction in DPP-4 level in 
sitgliptin (50 mg) treated group compared to control (Saline).  
 
DPP-4 (CD26) protein expression in high-fat diet animals 
 
No significant difference in DPP-4 (CD26) expression was observed in animal groups treated 
with sitagliptin (50 mg) dose, compared to the control. 
 
 
TRPV-1 and CGRP levels in heart tissues  
 
Sitagliptin (50 mg) treatment caused a significant increase in TRPV-1 level in normal animals, 
but not in high-fat diet ones, in comparison with the controls. Interestingly, CGRP levels 
increased significantly in animal groups treated with sitagliptin (50 mg) and in both diet 
conditions.  
Cardiac calcium content  
To determine whether the ischemic cardiac calcium concentration was affected by sitagliptin 
treatment, calcium level was measured calorimetrically, and obtained findings indicated an 
increase in calcium content in heart tissues assigned to drug therapy in normal and high-fat diet 
animals.  
Abundancy of TRPC-1 protein expression 
 
Animal group treated with sitagliptin (50 mg) dose showed a 3- fold higher level of TRPC-1 
expression in normolipidemic animals, while it was not the case in high-fat diet animals, and no 
significant change was observed.  
 
cNOS activity and e-NOS protein expression  
 
Two weeks daily oral treatment with Sitagliptin (50 mg) showed a significant increase in Nos 
activity in normal and high-fat diet animals, compared to the controls, however, results of e-NOS 
expression as determined by western blot showed an increased level of expression in sitagliptin 
(50 mg) treated animal group, in normal animals but not in high-fat diet groups. 
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Inhibitory effect of L-NAME on infarct size in normal and high-fat diet animals 
The infarct size- limiting effect of sitagliptin (50 mg) was abolished in animal groups co-treated 
with sitagliptin (50 mg) and NOS specific inhibitor (L-NAME) compared to animal groups 
treated groups with sitagliptin (50 mg) only, in normolipidemic and hyperlipidemic animals. An 
increase in size of infarction was observed in these groups.  
 
Inhibitory effect of capsazepine on infarct size in normolipidemic animals 
The infarct size- limiting effect of sitagliptin (50 mg) in normal animals was abolished upon its 
co-treatment with TRPV-1 specific inhibitor (capsazepine), compared to the animal groups 
treated with sitagliptin (50 mg) alone. The size of infarction increased significantly in these 
groups.  
 
Discussion 
In the present study, treatment with sitagliptin (50 mg) for 2 weeks successfully (i) attenuated 
infarct size (IS), increased NOS activity, CGRP level, and calcium content in both diets, (ii) 
reduced DPP-4 activity and DPP-4 level in normal and high-fat diet animals respectively. The 
upregulation of GLP-1 and TRPV-1 levels, e-NOS and TRPC-1 proteins expression in 
normolipidemic groups, were abolished under hyperlipidemic condition. Taking into account the 
results of the ineffective doses of sitagliptin, this drug can be considered clinical relevant for the 
treatment of ischemic diseases at a further level, after clarifying the molecular mechanisms 
underlying these doses. Although sitagliptin therapy seemed to be cardioprotective in 
normolipidemic animals and in some part in animals kept on high-fat diet, this drug may lose its 
efficacy in hyperlipidemic condition, when patients suffer from hyperlipidemia as a 
cardiovascular co-morbidity and risk factor.    
When the circulation is abruptly restored after a prolonged myocardial ischemia, this can lead to 
cardiomyocyte damage, which is commonly referred to myocardial I/R injury, triggered by 
neutrophil accumulation, causing ROS production and cellular damage. In the present study, 45 
min of regional ischemia and 120 min of reperfusion in sustained I/R injury, revealed a 
significant percentage of infarction (50-60 %). Accordingly, developing cytoprotective strategies 
in the frame of limiting myocardial infarction and maintaining a proper blood flow to the 
ischemic myocardial region is one of the main focuses of preclinical and clinical research. 
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Sitagliptin 50 mg showed a significant decrease in infarct size into 22 % and increase in cNOS 
activity in normal diet animals, as well as after high-fat diet enriched food. This DPP-4 inhibitor 
(DPP-4i)- mediated cardioprotective effect was lost after NOS-inhibition by L-NAME, under 
both diet conditions.  
Clinical investigations and experimental animal studies suggested that incretins, namely GLP-1 
can exhibit cardioprotective potentials following myocardial ischemia (MI). DPP-4 is abundantly 
expressed in the cardiovascular system and endothelial cells, and blocking its activity can have 
advantageous cardiovascular outcomes.  
DPP-4 inhibitors drugs were extensively studied in healthy animal models as a remedy against 
cardiovascular disorders, while their interventional mechanisms were poorly addressed in 
diseased animal models like hyperlipidemia. In our study, the effect of human- like 
hyperlipidaemia on development of myocardial infarction (MI) following coronary occlusion 
(Ischemia/Reperfusion- injury) was studied using the high-fat diet (HF) animals. Treatment with 
sitagliptin (50 mg) showed no decrease in serum cholesterol and triglyceride levels, however, a 
decrease in hepatic cholesterol was observed in sitagliptin treated group, compared to controls. 
After 45 min of regional ischemia and 2 hrs of reperfusion, only 39 % of the area at risk (AAR) 
became necrotic in hyperlipidemic vs. 44 % in normolipidemic animals. High-fat diet does not 
seem to increase the susceptibility of the myocardium to I/R injury, with the importance of early 
reperfusion after acute myocardial infarction (AMI) in normal and high-fat diet conditions.  
The peptide hormone GLP-1 was found to be highly abundant in the heart, exhibiting beneficial 
effects. Treatment with sitagliptin showed a significant decrease in DPP-4 activity in heart 
tissues from normolipidemic animals, and a significant decrease in DPP-4 level in heart tissues 
and aorta of high-fat diet groups. However, the expected increase in GLP-1 level was not the 
case in animals fed with high-fat diet, compared to the normal diet animals.  
The deleterious consequences of I/R injury can be a major cause of endothelial dysfunction, 
causing a reduction in endothelial nitric oxide synthase (e-NOS) expression, and prolonged 
myocardial ischemia was found to decrease cNOS activity and e-NOS expression. Our findings 
revealed an increase in e-NOS expression in ischemic hearts pre-treated with sitagliptin in 
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normal animals but not in high-fat diet ones. Hypercholesterolemia was found to be associated 
with impaired endothelial function in coronary circulation.    
The cardioprotective action of sitagliptin- mediated by NOS was confirmed by NOS inhibition, 
and this cardioprotective effect was abrogated when animals were co-treated with sitagliptin and 
NOS inhibitor (L-NAME), in both normal and high-fat diet animals.  
The up-regulatory effect of TRPC and TRPV channels was found to be associated with the 
pathophysiology of vascular and cardiac tissues. Our results are in disagreement with these 
findings, showing a significant increase in TRPV-1 TRPC-1 after sitagliptin treatment. 
Intraperitoneal administration of TRPV-1 inhibitor (capsazepine) blocked the infarct size 
limiting effect of sitagliptin.  
Stimulation of TRPV-1 promotes the release of calcitonin gene-related peptide (CGRP), with 
accumulating data reporting the advantageous role of CGRP in cardioprotection. This protective 
effect is in concordance with measurements from our study. The protective effect of sitagliptin 
mediated by TRPV/TRPC upregulation in normolipidemic animals was lost after a long-term 
high fat- diet consumption. CGRP increased significantly after prolonged high-fat diet regime 
and oral treatment with sitagliptin. To the best of our knowledge, this study was the first to show 
the upregulation of TRPV-1/CGRP axis in prolonged ischemia-reperfusion injury, using 
sitagliptin as a new targeting therapy, in normal and high-fat diet animals.   
 
Conclusions 
 
Sitagliptin treatment exhibited a: 
 
 
 Significant decrease in infarct size in both normolipidemic and hyperlipidemic animals.  
 
 Significant decreased in DPP-4 activity in normal animals but not in high-fat diet groups. 
 
 Significant increase in GLP-1 level was clearly observed in normal animals only.   
 
 Upregulation in heart NOS activity in animals from both diet conditions. 
 
 Significant increase in e-NOS expression in normal animals, but not in high-fat diet 
groups. 
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 Significant increase in TRPV-1 level and TRPC-1 expression in animals kept on normal 
diet.  
 
 Significant increase in calcitonin gene-related peptide in animal groups from both diets.  
 
 
The cardioprotective effect of sitagliptin- mediated by NOS was lost in both diet conditions, 
using NOS inhibitor. 
 
The cardioprotective effect of sitagliptin- mediated by TRPV-1 was also lost in normal 
animals, after TRPV-1 inhibition. 
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